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See Articles, pages 508–513 and 514–522Detection in the serum of the ‘‘Australia antigen”, namely hepa-
titis B surface antigen (HBsAg), was the Nobel prize discovery
that identiﬁed hepatitis B virus (HBV) about 40 years ago; to this
day HBsAg remains the hallmark of overt HBV infection [1,2].
HBsAg circulates in a wide array of particulate forms: competent
virions (42 nm, Dane particles), 20 nm diameter ﬁlaments of var-
iable length, and 20–22 nm spherical defective particles, corre-
sponding to empty viral envelopes [3]. Serum HBsAg results
from the different combinations of three proteins (small, medium
and large), either glycosylated or not, that are speciﬁed by a sin-
gle open reading frame providing 3 carboxy-terminal colinear
HBsAg proteins of different length. The small (S) protein (226
amino acids) is expressed at the highest levels, predominates in
both virions and subviral particles and is secreted without cleav-
age of amino acid residues during translocation because of its
self-assembling capacity with host-derived lipids in the cell ER
[4]. The middle (M) protein (containing 55 extra residues of the
pre-S2 domain) is regulated by the same promoter and is simi-
larly secreted, whereas the transcription of the large protein (L)
is regulated by a speciﬁc but weaker promoter (pre-S1) [5]. Hep-
atitis B virus large surface protein (L-HBs) containing both the
pre-S2 region and the 108–119 additional residues of the pre-
S1 domain, is an essential component of both virions and ﬁla-
ments, and represents 10–20% of their envelope proteins. In con-
trast, the L-HBs represents only 2% of the 22 nm spherical
particles [6,7]. The complexity of HBsAg production and secretion
is known since the early studies that showed a larger excess of
both ﬁlaments and spherical subviral particles was present in
highly viremic HBeAg positive carriers as compared to low vire-
mic anti-HBe positive carriers, in whom the decline of ﬁlaments
paralleled that of virions whereas spherical particles remained
in moderate excess [8,9]. Thus, subviral HBsAg particles exceed
virions by a variable factor of 102–105 and can accumulate up
to concentrations of several hundred micrograms per milliliter
of serum [3].
Quantiﬁcation of HBsAg was introduced more than 20 years
ago, but only recently has it been signiﬁcantly improved by
new automated quantitative assays [10]. Several studies suggest
a new potential role of quantitative serum HBsAg in the predic-
tion of virological response to antiviral therapy, at least in Peg-Journal of Hepatology 20
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identify non-responders as early as 12–24 weeks after the begin-
ning of treatment and to tailor treatment duration in responders
[12,13]. The correlations between HBsAg and HBV-DNA kinetics
are complex and variable in the different treatment settings;
the kinetics of the two parameters are dissociated in lamivudine
treated patients and relapsers to Peg-interferon, but parallel in
sustained responders to Peg-interferon [12,13]. Preliminary
reports on HBsAg and HBV-DNA serum levels in untreated acute
and chronic hepatitis B cases conﬁrm such a discrepancy, and lit-
tle is known about their relative variations along the highly
dynamic chronic HBV infection [14].
In this issue of the Journal, two manuscripts provide new
insights into serum HBsAg levels during chronic HBV infection
in Asian and European cohorts of HBV carriers. The novelty of
the works of Nguyen et al. [15] and Jaroszewicz et al. [16] stems
from their study on the correlations between HBsAg serum levels
and the clinical and virologic features of chronic HBV carriers
analysed in different phases of infection according to the most
recent criteria. Overall, 434 chronic carriers were studied: 62
immune-tolerant carriers (IT), 103 HBeAg positive patients in
the immune-clearance phase (IC), 118 HBeAg negative carriers
in the non-/low replicative phase (LC), and 151 patients with
HBeAg negative hepatitis (ENH). Two major ﬁndings are common
in the two studies: (1) median HBsAg levels differ signiﬁcantly
during the 4 phases of HBV infection and decline progressively
from IT (4.5–4.96 log 10 IU/ml in Asian and European carriers)
to LC (2.86–3.09 log 10 IU/ml in Asian and European carriers);
(2) HBsAg/HBV-DNA ratios are signiﬁcantly higher in LC (1.05
Asian–1.17 European) as compared to all the others patients
(ratios range 0.55–0.64). These ﬁndings entail that HBsAg secre-
tion is highly dynamic and varies along chronic HBV infection
both quantitatively and qualitatively. Accordingly, one intriguing
and complex issue remains the correlation between HBsAg and
HBV-DNA serum levels. In spite of an overall correlation in the
European cohort (R = 0.75, p < 0.001), the two parameters show
weaker or absent correlations when the different phases of HBV
infection are analysed separately or by HBV genotype. A negative
correlation is reported in genotype A HBeAg positive (IC,
R = 0.24) and negative (ENH, R = 0.07) patients, a positive rela-
tion in genotype B, C and D ENH, in genotype B and C IT and in
genotype A and D LC, but all the correlation coefﬁcients are poor
(R ranging from 0.29 to 0.57). On the contrary, in genotype B and
C HBeAg positive patients (IC) HBsAg and HBV-DNA serum levels10 vol. 52 j 475–477
Fig. 1. Clinical signiﬁcance of quantiﬁcation and decline of serum HBV-DNA
and HBsAg. HBV-DNA serum levels parallel the ﬂuctuations of HBV replication
during the different phases of HBV infection whereas HBsAg serum levels are
expression of transcriptionally active cccDNA and decline gradually over time
during HBV infection.
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correlate signiﬁcantly (p = 0.0001) and with better coefﬁcient
(R = 0.77), as well as in 12 European patients with acute hepatitis
B (R = 0.79). These data suggest direct interactions between HBV
genotype, HBsAg serum level and viral load. Accordingly, geno-
type-speciﬁc patterns of expression of intracellular and extracel-
lular viral DNA and antigens were shown by transfection of Huh7
[17]. In vitro, genotype A showed a sharp dissociation between
HBsAg and HBV-DNA production, with the highest HBsAg secre-
tion combined with the lowest HBV-DNA production in the cul-
ture medium [17]. Larger studies are needed to address the
correlations between HBV genotypes and the dynamics of HBsAg
serum levels during the different phases of HBV infection. In spite
of the possible limitation of genotype interference, it is interest-
ing to note that HBsAg and HBV-DNA serum levels showed their
highest correlation in the early phases of immune clearance,
namely in acute hepatitis B and in HBeAg positive CHB (IC)
[15,16]. These ﬁndings, together with the parallel kinetics of
HBsAg and HBV-DNA in patients responding to Peg-IFN treat-
ment [12,13], suggest that virion and HBsAg antigen production
correlate better when they are concordantly inhibited by a strong
immune-response resulting in the efﬁcient control of viral repli-
cation, namely HBeAg/anti-HBe or HBsAg/anti-HBs seroconver-
sion. If the immune clearance does not succeed in the complete
control of HBV infection, leading to HBsAg clearance and anti-
HBs seroconversion, HBV infection evolves into the low replica-
tive phase or HBeAg negative CHB. In both conditions, the dis-
crepancy between HBV-DNA and HBsAg production may
increase for several reasons but it is primarily due to the produc-
tion of defective particles that outnumber the virions during the
low replicative phase, as already shown in the older studies,
where lower amounts of serum L-HBs (the hallmark of the sur-
face protein of the virion and ﬁlaments) were found in non-vire-
mic as compared to viremic HBV carriers [8,9]. The higher HBsAg/
HBV-DNA ratios found by Nguyen and Jaroszewicz in LC are con-
sistent with the previous data, suggesting a relatively lower pro-
duction of virions versus subviral HBs antigens in this subset of
carriers. This might depend on a stronger inhibition of pre-gen-
ome transcription from intrahepatic cccDNA as compared to the
envelope protein mRNAs, or to the defective secretion of virions
as a consequence of the emergence of HBV mutants, which are
selected by the long lasting immune pressure on the HBsAg gene
that may deregulate HBsAg expression with an asymmetric pro-
duction of S, M and L proteins [18,19]. Indeed an inverse relation-
ship was reported between serum HBsAg levels and the
intrahepatic cytoplasmic storage of HBsAg (ground glass cells)
[14]. In fact, overexpression of L-HBs can cause S protein to accu-
mulate in the Golgi complex and to inhibit the secretion of HBsAg
particles, as a proper stoichiometry between L and S proteins is
required for the secretion of HBsAg and virions [18,19]. Finally
a role of integrated HBV-DNA in the alteration of HBsAg secretion
was also advocated [20].
In conclusion, HBsAg serum levels are the resultant of the
complex equilibrium between the virus and the host’s immune
system as well as the product of the transcription of speciﬁc
mRNAs rather than viral replication. Thus, we may speculate that
serum HBsAg is the indirect expression of transcriptionally active
cccDNA rather than total intrahepatic cccDNA. Of course, we can-
not exclude a role of integrated HBV-DNA in HBsAg synthesis;
however, the evidence that HBsAg serum levels decline signiﬁ-
cantly with the duration of HBV infection, when the amount of
integrated HBV-DNA is supposed to increase, weakens such a476 Journal of Hepatology 201hypothesis. The substantial variations of total serum HBsAg in
the different phases of HBV infection proposes quantitative
HBsAg as a new diagnostic tool for the characterization of the
HBV carrier in combination with HBV-DNA. The two HBV mark-
ers providing complementary information on the status of HBV
infection (Fig. 1) may be very useful in clinical practice to deﬁne
the speciﬁc condition of the single HBV carrier during the highly
dynamic phases of chronic HBV infection, just as latitude and lon-
gitude allow to deﬁne the ship’s position in the ocean. This will be
of paramount importance to avoid the misclassiﬁcation of an
asymptomatic HBeAg negative CHB patient as an inactive carrier
because of a single point serum test with normal transaminases
and negative HBV-DNA caused by the typical intermittent disease
proﬁle of HBeAg negative CHB.
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